Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-25T15:24:17.913Z Has data issue: false hasContentIssue false
  • English
  • Français

Incidence and Risk Factors for Infection Following Transcatheter Aortic Valve Implantation

Published online by Cambridge University Press:  20 June 2016

Yuhao Shi ,
Harindra C. Wijeysundera ,
Stephen E. Fremes  and
Andrew E. Simor
Yuhao Shi
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Harindra C. Wijeysundera
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Division of Cardiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Stephen E. Fremes
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Division of Cardiac Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Andrew E. Simor*
Affiliation:
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Department of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
*
Address correspondence to Dr. Andrew E. Simor, Department of Microbiology, Sunnybrook Health Sciences Centre, B103-2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5 (andrew.simor@sunnybrook.ca).
Get access Rights & Permissions [Opens in a new window]

Abstract

We identified risk factors for infection following transcatheter aortic valve implantation (TAVI); infection occurred in 35 (13.8%) of 253 patients. Variables associated with infection included chronic obstructive pulmonary disease (OR, 1.2; 95% CI, 1.1–1.4), postprocedural hemorrhage (OR, 1.2; 95% CI, 1.0–1.3), and procedure-related stroke (OR, 1.6; 95% CI, 1.3–2.1).

Infect Control Hosp Epidemiol 2016;37:1094–1097

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 37 , Issue 9 , September 2016 , pp. 1094 - 1097
Copyright
© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.Google Scholar
2. Kappetein, AP, Head, SJ, Généreux, P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation. The Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012;60:1438–1454.Google Scholar
3. Van Mieghem, NM, van der Boon, RM, Nuis, R-J, et al. Cause of death after transcatheter aortic valve implantation. Cath Cardiovasc Interv 2014;83:E277–E282.Google Scholar
4. van der Boon, RMA, Nuis, R-J, Benitez, LM, et al. Frequency, determinants and prognostic implications of infectious complications after transcatheter aortic valve implantation. Am J Cardiol 2013;112:104–110.Google Scholar
5. Barbash, IM, Finkelstein, A, Barsheshet, A, et al. Outcomes of patients at estimated low, intermediate, and high risk undergoing transcatheter aortic valve implantation for aortic stenosis. Am J Cardiol 2015;116:1916–1922.Google Scholar
6. Amat-Santos, IJ, Messika-Zeitoun, D, Eltchaninoff, H, et al. Infective endocarditis after transcatheter aortic valve implantation. Results from a large multicenter registry. Circulation 2015;131:1566–1574.Google Scholar
7. Olsen, NT, de backer, O, Thyregod, HGH, et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2015;8:e001939. DOI:10.1161/circinterventions.114.001939.Google Scholar
8. Biancari, F, Rosato, S, D’Errigo, P, et al. Immediate and intermediate outcome after transapical versus transfemoral transcatheter aortic valve replacement. Am J Cardiol 2016;117:245–251.Google Scholar
9. Van Mieghem, NM, Tchetche, D, Chieffo, A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012;110:1361–1367.Google Scholar
10. Egron, S, Kütting, M, Marzelle, J, Becquemin, JP, Schmitz-Rode, T, Steinseifer, U. What can be done for cerebral embolic protection in TAVI? Analysis in the light of 10 years’ experience with protected carotid artery stenting. Expert Rev Med Devices 2016;13:15–29.Google Scholar
Supplementary material: File

Shi supplementary material

Table

Download Shi supplementary material(File)
File 16.4 KB